Skip to main content

Chemspeed acquired by Bruker

| News

Chemspeed acquired by Bruker


Chemspeed Technologies is to be integrated in Bruker, the US manufacturer of instruments used in life sciences research. The specialist for automated lab solutions based in the canton of Basel-Landschaft will continue to operate as an independent entity within Bruker.

Chemspeed headquarters in Füllinsdorf in the canton of Basel-Landschaft (image: Chemspeed)

Bruker, the manufacturer of scientific instruments for molecular and materials research, diagnostics and industry based in the US State of Massachusetts, has finalized the acquisition of Chemspeed Technologies AG. As the company has now announced, this takeover of the global specialists in lab automation from the canton of Basel-Landschaft, news of which first broke in January 2024, marks a significant milestone in its expansion plans.

“We are excited about the opportunities this acquisition brings, and we warmly welcome the excellent Chemspeed team to Bruker”, comments Bernd Gleixner, President of the new Automation Division at Bruker BioSpin and newly appointed Managing Director of Chemspeed. “Going forward, Chemspeed will continue to operate as a vendor-agnostic, standalone business within Bruker, maintaining its commitment to industry-leading automated laboratory solutions and customer service”, he adds.

Organic sales growth expected

As part of Bruker, Chemspeed is expected to be near break-even across the remaining three quarters of 2024 with sales of approximately 10 million US dollars per quarter. For the future, the company expects Chemspeed to achieve organic sales growth in the high single-digit to low double-digit range, in addition to steady, significant margin growth.

Find out more about Chemspeed and their innovative approach to automation in chemistry and robotics

Applied chemistry and robotics in research and development – were they made for each other? Automation and robotics are transforming many workplaces – including chemical labs. What can be achieved, if automated dosage, synthesis, formulation, application, testing is no longer a dream but practical reality? We talked to Lucius Kemp from Clariant, Professor Andy. I. Cooper FRS, from Materials Innovation Factory & Leverhulme Centre for Functional Materials Design and Rolf Gueller from Chemspeed Technologies AG about different aspects and experiences.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.